Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
This summary integrates evidence supporting a strong association between SHOX2 and atrial fibrillation. Multiple independent studies have identified SHOX2 variants in patients with familial and early‑onset atrial fibrillation. A key case‑report revealed a heterozygous loss‑of‑function mutation that co‑segregated with the disease in a family, with testing demonstrating complete penetrance (PMID:30443179). The study screened 162 unrelated familial AF patients and uncovered novel pathogenic variants that were absent in control chromosomes, highlighting the gene’s role in arrhythmogenesis.
In addition to the case‑report, multi‑patient studies have provided compelling genetic evidence. Analysis of 378 early‑onset AF patients identified both missense and non‑coding variants in SHOX2, including recurrent alleles that impact protein function (PMID:27138930). Further investigations in cohorts with sinus node dysfunction and atrial fibrillation identified several additional rare variants. These findings underscore that diverse mutation types in SHOX2 play a significant role in the genetic architecture of these arrhythmias (PMID:31354791).
The summarized variant spectrum includes a representative nonsense variant, c.508C>T (p.Arg170Ter), which exemplifies the loss‑of‑function mechanism. This variant was rigorously evaluated and demonstrated to abolish transcriptional activity in functional studies. Co‑segregation analysis in the index family further supports its pathogenicity, with multiple affected relatives carrying the mutant allele, thereby reinforcing the autosomal dominant inheritance pattern of the disorder (PMID:30443179).
Experimental assays provide critical complementary evidence. Functional characterization employing dual‑luciferase reporter assays and zebrafish models has shown that SHOX2 mutations lead to a significant reduction in transcriptional activity, aligning with the observed clinical phenotype. Furthermore, phosphorylation studies indicate that regulation of SHOX2 function through post‑translational modifications is essential for normal sinoatrial node development (PMID:24847033). These data support haploinsufficiency as the primary disease mechanism.
Collectively, both genetic and functional data coalesce around a strong causative role for SHOX2 in atrial fibrillation. The evidence spans robust familial segregation, a spectrum of variant types, and multiple independent functional demonstrations, all of which enhance the clinical validity of this gene‑disease association.
No significant conflicting evidence has been reported; however, ongoing studies continue to refine the penetrance and expressivity of SHOX2 variants. The accumulation of evidence exceeds the standard ClinGen scoring maximum, providing additional support not fully encapsulated by the formal criteria.
Key take‑home: SHOX2 is strongly implicated in the etiology of familial atrial fibrillation, making it a valuable target for diagnostic screening and precision management of patients with arrhythmia.
Gene–Disease AssociationStrongMultiple studies revealed SHOX2 variants in familial and early‑onset AF with robust segregation evidence and concordant functional data (PMID:30443179, PMID:27138930, PMID:31354791). Genetic EvidenceStrongGenetic support is derived from a representative nonsense mutation, c.508C>T (p.Arg170Ter), which co‑segregates with disease in familial cases and is complemented by the identification of additional rare variants in large AF cohorts. Functional EvidenceStrongFunctional assays, including dual‑luciferase reporter studies and animal models, consistently demonstrated loss of SHOX2 activity, substantiating a haploinsufficiency mechanism (PMID:24847033). |